A new series of 3-(1,3-disubstituted-1H-pyrazole-4-carbonyl)-1,7-diphenyl-[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones 4 was prepared by reaction of the enaminone 2 with hydrazonoyl halides 3. The preliminary screening for antitumor activity of the synthesized compounds was carried out against Ehrlich Ascites Carcinoma tumor cells. The results revealed that the studied compounds 4 have low or no antitumor activity towards EAC tumor cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12272-010-2224-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inotodiol induces hepatocellular carcinoma apoptosis by activation of MAPK/ERK pathway.
PLoS One
January 2025
Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, China.
Hepatocellular carcinoma(HCC) has a high mortality and morbidity rate and seriously jeopardizes human life. Chemicals and chemotherapeutic agents have been experiencing problems such as side effects and drug resistance in the treatment of HCC, which cannot meet the needs of clinical treatment. Therefore, finding novel low-toxicity and high-efficiency anti-hepatocellular carcinoma drugs and exploring their mechanisms of action have become the current problems to be solved in the treatment of HCC.
View Article and Find Full Text PDFIntralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy.
Drug Deliv Transl Res
January 2025
Kinimmune, Inc. St. Louis, 63141, Missouri, USA.
PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure.
View Article and Find Full Text PDFA bifunctional antibody targeting PD-1 and TGF-β signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury.
Cancer Immunol Res
January 2025
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Radio-immunotherapy has antitumor activity but also causes toxicity, which limits its clinical application. JS-201 is a dual antibody targeting PD-1 and TGF-β signaling. We investigated the antitumour effect of JS-201 combined with radiotherapy and the effect on radiation-induced lung injury (RILI).
View Article and Find Full Text PDFExploring Pyridine-Based Schemes: A Comprehensive Review on their Synthesis and Therapeutic Applications.
Med Chem
January 2025
Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.
Pyridine and its derivatives are six-membered aromatic rings containing nitrogen, which are abundant in nature and indispensable in studying heterocyclic chemistry. They constitute significant chemical substances with numerous applications. The application of pyridine derivatives by incorporating metals in modern medicine is growing in relevance.
View Article and Find Full Text PDFA phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer.
Anticancer Drugs
January 2025
Oncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Article Synopsis
- Anlotinib has demonstrated positive effects in treating platinum-resistant ovarian cancer, but its role as a maintenance therapy after initial treatment was unclear.
- In a phase II clinical trial with 24 patients, those who received anlotinib after responding to chemotherapy had a median progression-free survival of 15.8 months and an overall survival of 43.8 months.
- The study indicated that anlotinib is a safe and effective option for maintenance therapy, showing promise in extending survival for patients with advanced ovarian cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!